Oxaliplatin

Podcast: The Art and Science of Oncology in Rectal Cancer Treatment

Podcast file: 

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

How aggressive should the chemo for rectal cancer be? A newly published study doesn't make the question any easier.

Publishing in Lancet Oncology, a British group treated patients with a combination of Xeloda and oxaliplatin initially, then Xeloda and radiation, then surgery.

In the 105 patients studied with poor risk disease, recurrences were rare at five years.

How to treat rectal cancer: let the controversy continue

How aggressive should the chemo for rectal cancer be? A newly published study doesn't make the question any easier.

Publishing in Lancet Oncology, a British group treated patients with a combination of Xeloda and oxaliplatin initially, then Xeloda and radiation, then surgery.

In the 105 patients studied with poor risk disease, recurrences were rare at five years.

Haller: Xelox new standard of care in early colon cancer

The finDaniel G. Haller, MDdings were presented today at the ASCO GI malignancies symposium that disease free survival was improved with oral Xeloda versus conventional intravenous 5FU in patients with early colon cancer. Dr. Daniel Haller from University of Pennsylvania presented the data; he has been working on colon cancer research protocols for many years.

The media perhaps overreacted to the news: headlines such as

Syndicate content